Ribavirin can be mutagenic for arenaviruses

Journal of Virology

Volumn 85, Issue 14, 2011, Pages 7246-7255

  Moreno, Héctor ^a,b   Gallego, Isabel ^a   Sevilla, Noemí ^c   de la Torre, Juan Carlos ^b   Domingo, Esteban ^a,d   Martín, Verónica ^a,c  

^a CSIC   (Spain)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATE; INOSINATE DEHYDROGENASE; RIBAVIRIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MUTAGENIC ACTIVITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ANTIVIRAL AGENTS; ARENAVIRUS; BASE SEQUENCE; CELL LINE; CRICETINAE; DNA PRIMERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN;

ARENAVIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

EID: 79960387914     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00614-11     Document Type: Article

References (99)

1. Acosta, E. G., et al. 2008. Dehydroepiandrosterone, epiandrosterone and synthetic derivatives inhibit Junin virus replication in vitro. Virus Res. 135: 203-212.
2. Agudo, R., et al. 2008. Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J. Mol. Biol. 382:652-666.
3. Agudo, R., et al. 2010. A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog. 6(8):e1001072.
4. Ahmed, R., et al. 1988. Genetic analysis of in vivo-selected viral variants causing chronic infection: importance of mutation in the L RNA segment of lymphocytic choriomeningitis virus. J. Virol. 62:3301-3308.
5. Airaksinen, A., N. Pariente, L. Menendez-Arias, and E. Domingo. 2003. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311:339-349.
6. Anderson, J. P., R. Daifuku, and L. A. Loeb. 2004. Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol. 58:183-205.
7. Arias, A., et al. 2008. Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J. Virol. 82:12346-12355.
8. Asahina, Y., et al. 2005. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J. Hepatol. 43:623-629.
9. Barton, L. L. 1996. Lymphocytic choriomeningitis virus: a neglected central nervous system pathogen. Clin. Infect. Dis. 22:197.
10. Bonhoeffer, S., R. M. May, G. M. Shaw, and M. A. Nowak. 1997. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. U. S. A. 94:6971-6976.
11. Bowen, M. D., C. J. Peters, and S. T. Nichol. 1997. Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol. Phylogenet. Evol. 8:301-316.
12. Briese, T., et al. 2009. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog. 5:e1000455.
13. Buchmeier, M. J., J. C. de la Torre, and C. J. Peters. 2007. Arenaviridae: the viruses and their replication, p. 1791-1827. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
14. Chevaliez, S., R. Brillet, E. Lazaro, C. Hezode, and J. M. Pawlotsky. 2007. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol. 81:7732-7741.
15. Connor, E., et al. 1993. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 37:532-539.
16. Contreras, A. M., et al. 2002. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 76:8505-8517.
17. Crotty, S., C. E. Cameron, and R. Andino. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U. S. A. 98:6895-6900.
18. Crotty, S., et al. 2000. The broad-spectrum antiviral ribonucleotide, ribavirin, is an RNA virus mutagen. Nat. Med. 6:1375-1379.
19. Cubero, M., et al. 2008. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 370:237-245.
20. Cuevas, J. M., F. Gonzalez-Candelas, A. Moya, and R. Sanjuan. 2009. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol. 83:5760-5764.
21. Cummings, K. J., et al. 2001. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 285:193-199.
22. Davis, G. L., et al. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1493-1499.
23. Di Bisceglie, A. M., J. Thompson, N. Smith-Wilkaitis, E. M. Brunt, and B. R. Bacon. 2001. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 33:704-707.
24. Domingo, E. (ed.). 2005. Virus entry into error catastrophe as a new antiviral strategy. Virus Res. 107:115-228.
25. Dusheiko, G., D. Nelson, and K. R. Reddy. 2008. Ribavirin considerations in treatment optimization. Antivir. Ther. 13(Suppl. 1):23-30.
26. Dutko, F. J., and M. B. A. Oldstone. 1983. Genomic and biologic variation among commonly used lymphocytic choriomeningitis virus strains. J. Gen. Virol. 64:1689-1694.
27. Emonet, S., J. J. Lemasson, J. P. Gonzalez, X. de Lamballerie, and R. N. Charrel. 2006. Phylogeny and evolution of old world arenaviruses. Virology 350:251-257.
28. Emonet, S. F., J. C. de la Torre, E. Domingo, and N. Sevilla. 2009. Arenavirus genetic diversity and its biological implications. Infect. Genet. Evol. 9:417-429.
29. Enria, D. A., and J. I. Maiztegui. 1994. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 23:23-31.
30. Ferrer-Orta, C., et al. 2010. Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J. Virol. 84:6188-6199.
31. Fischer, S. A., et al. 2006. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 354:2235-2249.
32. Fox, E. J., and L. A. Loeb. 2010. Lethal mutagenesis: targeting the mutator phenotype in cancer. Semin. Cancer Biol. 20:353-359.
33. Franklin, T. J., and J. M. Cook. 1969. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem. J. 113:515-524.
34. González-López, C., A. Arias, N. Pariente, G. Gómez-Mariano, and E. Domingo. 2004. Preextinction viral RNA can interfere with infectivity. J. Virol. 78:3319-3324.
35. González-López, C., G. Gómez-Mariano, C. Escarmís, and E. Domingo. 2005. Invariant aphthovirus consensus nucleotide sequence in the transition to error catastrophe. Infect. Genet. Evol. 5:366-374.
36. Gowen, B. B., et al. 2008. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 3:e3725.
37. Graci, J. D., and C. E. Cameron. 2006. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16:37-48.
38. Graci, J. D., and C. E. Cameron. 2008. Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol. 3:553-566.
39. Grande-Pérez, A., G. Gómez-Mariano, P. R. Lowenstein, and E. Domingo. 2005. Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J. Virol. 79:10451-10459.
40. Grande-Pérez, A., E. Lazaro, P. Lowenstein, E. Domingo, and S. C. Manrubia. 2005. Suppression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. U. S. A. 102:4448-4452.
41. Grande-Pérez, A., S. Sierra, M. G. Castro, E. Domingo, and P. R. Lowenstein. 2002. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc. Natl. Acad. Sci. U. S. A. 99:12938-12943.
42. Iranzo, J., and S. C. Manrubia. 2009. Stochastic extinction of viral infectivity through the action of defectors. Europhys. Lett. 85:18001.
43. Jahrling, P. B., et al. 1980. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 141:580-589.
44. Jahrling, P. B., C. J. Peters, and E. L. Stephen. 1984. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J. Infect. Dis. 149:420-427.
45. Jamieson, D. J., A. P. Kourtis, M. Bell, and S. A. Rasmussen. 2006. Lymphocytic choriomeningitis virus: an emerging obstetric pathogen? Am. J. Obstet. Gynecol. 194:1532-1536.
46. Johnson, J. A., et al. 2008. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 5:e158.
47. Jordan, I., T. Briese, N. Fischer, J. Y. Lau, and W. I. Lipkin. 2000. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J. Infect. Dis. 182:1214-1217.
48. Kanda, T., et al. 2004. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J. Viral. Hepat. 11:479-487.
49. Kenyon, R. H., P. G. Canonico, D. E. Green, and C. J. Peters. 1986. Effect of ribavirin and tributylribavirin on Argentine hemorrhagic fever (Junin virus) in guinea pigs. Antimicrob. Agents Chemother. 29:521-523.
50. Kerr, S. J. 1987. Ribavirin induced differentiation of murine erythroleukemia cells. Mol. Cell. Biochem. 77:187-194.
51. Kilgore, P. E., et al. 1997. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin. Infect. Dis. 24:718-722.
52. Kuntzen, T., et al. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778.
53. Kunz, B. A., et al. 1994. International Commission for Protection Against Environmental Mutagens and Carcinogens. Deoxyribonucleoside triphosphate levels: a critical factor in the maintenance of genetic stability. Mutat. Res. 318:1-64.
54. Lanford, R. E., et al. 2001. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75:8074-8081.
55. Lee, A. M., et al. 2008. Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Virology 372:107-117.
56. Le Moing, V., et al. 2002. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 16:21-29.
57. Leyssen, P., J. Balzarini, E. De Clercq, and J. Neyts. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79:1943-1947.
58. Leyssen, P., E. De Clercq, and J. Neyts. 2008. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res. 78:9-25.
59. Leyssen, P., E. De Clercq, and J. Neyts. 2006. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol. Pharmacol. 69:1461-1467.
60. Lucia, H. L., D. H. Coppenhaver, and S. Baron. 1989. Arenavirus infection in the guinea pig model: antiviral therapy with recombinant interferon-alpha, the immunomodulator CL246,738 and ribavirin. Antiviral Res. 12:279-292.
61. Lutchman, G., et al. 2007. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 132:1757-1766.
62. Maag, D., C. Castro, Z. Hong, and C. E. Cameron. 2001. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276:46094-46098.
63. Martin, V., D. Abia, E. Domingo, and A. Grande-Perez. 2010. An interfering activity against lymphocytic choriomeningitis virus replication associated with enhanced mutagenesis. J. Gen. Virol. 91:990-1003.
64. Martín, V., A. Grande-Pérez, and E. Domingo. 2008. No evidence of selection for mutational robustness during lethal mutagenesis of lymphocytic choriomeningitis virus. Virology 378:185-192.
65. Martínez, M. A., J. P. Vartanian, and S. Wain-Hobson. 1994. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc. Natl. Acad. Sci. U. S. A. 91:11787-11791.
66. McCormick, J. B., et al. 1986. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314:20-26.
67. McHutchison, J. G., et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1485-1492.
68. Mendenhall, M., et al. 2011. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob. Agents Chemother. 55:782-787.
69. Moriyama, K., et al. 2008. Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity. J. Med. Chem. 51:159-166.
70. Müller, V., and S. Bonhoeffer. 2008. Intra-host dynamics and evolution of HIV infections, p. 279-302. In E. Domingo, C. R. Parrish, and J. J. Holland (ed.), Origin and evolution of viruses, 2nd ed. Academic Press, London, United Kingdom.
71. Nijhuis, M., N. M. van Maarseveen, and C. A. Boucher. 2009. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb. Exp. Pharmacol. 189:299-320.
72. Oldstone, M. B. A. (ed.). 2002. Current topics in microbiology and immunology, vol. 262. Arenaviruses I. Springer-Verlag, Berlin, Germany.
73. Oldstone, M. B. A. (ed.). 2002. Current topics in microbiology and immunology, vol. 263. Arenaviruses II. Springer-Verlag, Berlin, Germany.
74. Palacios, G., et al. 2008. A new arenavirus in a cluster of fatal transplantassociated diseases. N. Engl. J. Med. 358:991-998.
75. Pariente, N., A. Airaksinen, and E. Domingo. 2003. Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J. Virol. 77:7131-7138.
76. Parker, W. B. 2005. Metabolism and antiviral activity of ribavirin. Virus Res. 107:165-171.
77. Perales, C., R. Agudo, S. C. Manrubia, and E. Domingo. 2011. Influence of mutagenesis and viral load in sustained, low-level replication of an RNA virus. J. Mol. Biol. 407:60-78.
78. Perales, C., R. Agudo, H. Tejero, S. C. Manrubia, and E. Domingo. 2009. Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog. 5:e1000658.
79. Perelson, A. S., and T. J. Layden. 2007. Ribavirin: is it a mutagen for hepatitis C virus? Gastroenterology 132:2050-2052.
80. Pfeiffer, J. K., and K. Kirkegaard. 2005. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J. Virol. 79:2346-2355.
81. Popescu, M., H. Schaefer, and F. Lehmann-Grube. 1976. Homologous interference of lymphocytic choriomeningitis virus: detection and measurement of interference focus-forming units. J. Virol. 20:1-8.
82. Ruiz-Jarabo, C. M., C. Ly, E. Domingo, and J. C. de la Torre. 2003. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308:37-47.
83. Sánchez, G., A. Bosch, G. Gómez-Mariano, E. Domingo, and R. Pinto. 2003. Evidence for quasispecies distributions in the human hepatitis A virus genome. Virology 315:34-42.
84. Schmitz, H., et al. 2002. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect. 4:43-50.
85. Severson, W. E., C. S. Schmaljohn, A. Javadian, and C. B. Jonsson. 2003. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 77:481-488.
86. Sevilla, N., and J. C. de la Torre. 2006. Arenavirus diversity and evolution: quasispecies in vivo. Curr. Top. Microbiol. Immunol. 299:315-335.
87. Sidwell, O. W., L. N. Simon, J. T. Witkowski, and R. K. Robins. 1974. Antiviral activity of virazole: review and structure-activity relationships. Prog. Chemother. 2:889-903.
88. Sierra, M., et al. 2007. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol. 81:2012-2024.
89. Smee, D. F., et al. 1993. Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen. Antiviral Res. 20:57-70.
90. Smith, R. A., and W. Kirkpatrick. 1980. Ribavirin: a broad spectrum antiviral agent. Academic Press, Inc., New York, NY.
91. Snell, N. J. 2001. Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin. Pharmacother. 2:1317-1324.
92. Streeter, D. G., et al. 1973. Mechanism of action of 1-β-D-ribofuranosyl1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U. S. A. 70:1174-1178.
93. Tapia, N., et al. 2005. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology 338:1-8.
94. Van Vaerenbergh, K., et al. 2002. Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. AIDS Res. Hum. Retroviruses 18:419-426.
95. Volkenstein, M. V. 1994. Physical approaches to biological evolution. SpringerVerlag, Berlin, Germany.
96. Welsh, R. M., et al. 1975. A comparison of biochemical and biological properties of standard and defective lymphocytic choriomeningitis virus. Bull. World Health Organ. 52:403-408.
97. Welsh, R. M., C. M. O'Connell, and C. J. Pfau. 1972. Properties of defective lymphocytic choriomeningitis virus. J. Gen. Virol. 17:355-359.
98. Zhou, S., R. Liu, B. M. Baroudy, B. A. Malcolm, and G. R. Reyes. 2003. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310:333-342.
99. Zimmerman, T. P., and R. D. Deeprose. 1978. Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells. Biochem. Pharmacol. 27:709-716.